continu
improv
vaccin
technolog
led
remark
progress
control
human
infecti
diseas
fundament
view
natur
vaccin
chang
discoveri
dna
immun
earli
determin
genet
materi
encod
antigen
rather
actual
antigen
effect
elicit
immun
respons
given
ever
increas
threat
emerg
reemerg
infecti
diseas
renew
concern
regard
use
biolog
agent
bioterror
purpos
opportun
dna
vaccin
technolog
provid
could
come
critic
time
histori
sinc
incept
dna
vaccin
technolog
undergon
signific
advanc
mani
candid
human
vaccin
formul
alreadi
develop
improv
mode
administr
use
codon
antigen
gene
optim
implement
vaccin
dna
primeboost
regimen
led
quick
progress
dna
vaccin
research
laboratori
bench
human
clinic
trial
signific
progress
made
develop
dna
vaccin
variou
biodefens
emerg
infecti
diseas
target
influenza
sever
acut
respiratori
syndrom
associ
domin
design
previou
gener
vaccin
final
dna
vaccin
ideal
tool
screen
new
optim
protect
antigen
pa
formul
new
improv
vaccin
emerg
neglect
infecti
diseas
bioterror
sinc
discoveri
dna
vaccin
earli
well
recogn
novel
immun
technolog
possess
follow
key
strength
eas
construct
product
construct
nativ
conform
vivo
express
protein
antigen
includ
associ
posttransl
process
newli
synthes
protein
glycosyl
flexibl
modifi
antigen
sequenc
match
mutat
pathogen
gene
produc
optim
design
antigen
abil
elicit
cellmedi
humor
immun
respons
overal
good
safeti
profil
potenti
deliv
multipl
antigen
gene
one
construct
mixtur
multipl
plasmid
past
year
immunogen
dna
vaccin
improv
util
sever
key
technolog
advanc
includ
antigen
gene
codon
code
sequenc
optim
variou
dna
deliveri
method
adopt
primeboost
regimen
critic
step
dna
vaccin
establish
high
level
gene
express
mammalian
host
one
way
improv
immunogen
dna
vaccin
alter
nucleic
acid
sequenc
viral
dna
better
complement
genet
makeup
mammalian
host
keep
amino
acid
process
call
codon
optim
basi
use
codon
optim
dna
vaccin
design
stem
idea
mani
amino
acid
code
one
codon
frequenc
mammalian
host
may
use
particular
codon
may
differ
usag
earli
sever
research
group
discov
independ
direct
inocul
dna
plasmid
code
specif
protein
antigen
could
elicit
immun
respons
antigen
tang
et
al
robinson
et
al
ulmer
et
al
wang
et
al
lu
et
al
dna
nucleic
acid
vaccin
consid
fourth
gener
vaccin
live
attenu
vaccin
inactiv
vaccin
recombin
proteinbas
vaccin
new
vaccin
technolog
could
come
import
time
histori
given
increas
threat
emerg
reemerg
infecti
diseas
renew
concern
regard
use
biolog
agent
bioterror
purpos
need
immunolog
protect
larg
popul
would
requir
product
stockpil
larg
quantiti
vaccin
futur
vaccin
need
effect
maintain
high
safeti
profil
design
vaccin
flexibl
counter
antigen
alter
protect
peopl
one
type
pathogen
dna
vaccin
ideal
vaccin
system
employ
face
challeng
dna
vaccin
util
eukaryot
express
vector
express
gene
product
multipl
gene
product
vivo
express
system
serv
deliveri
system
produc
either
secret
cellassoci
antigen
goal
elicit
optim
antigenspecif
humor
cellmedi
immun
respons
host
past
year
dna
vaccin
technolog
gone
signific
improv
focu
research
gradual
shift
proofofconcept
studi
anim
model
demonstr
immunogen
human
dna
vaccin
technolog
provid
research
uniqu
platform
effect
achiev
three
import
object
develop
next
gener
vaccin
emerg
infecti
diseas
pathogen
potenti
use
bioterror
agent
first
dna
vaccin
simpl
altern
option
pathogen
effect
vaccin
past
origin
manufactur
process
longer
consid
safe
second
dna
vaccin
abl
elicit
improv
cellmedi
immun
respons
addit
protect
antibodi
respons
coronaviru
sarscov
ebola
viral
encephalitid
anthrax
plagu
botul
among
other
alreadi
move
earli
phase
clinic
trial
promis
result
abil
respond
potenti
bioterror
threat
emerg
infecti
diseas
outbreak
crucial
advanc
associ
dna
vaccin
technolog
allow
us
prompt
ration
matter
viru
variou
studi
use
knowledg
order
improv
abil
mammalian
cell
express
viral
protein
haa
et
al
andr
et
al
kotsopoul
et
al
liu
et
al
apt
et
al
wang
et
al
wang
et
al
method
alter
genet
sequenc
proven
effect
increas
immunogen
variou
dna
vaccin
human
immunodefici
viru
hiv
haa
et
al
andr
et
al
kotsopoul
et
al
liu
et
al
wang
et
al
influenza
viru
wang
et
al
dengu
viru
due
increas
overal
antigen
product
result
enhanc
mrna
stabil
wang
et
al
better
util
hostcel
trna
haa
et
al
due
adapt
codon
optim
otherwis
low
effici
dna
express
vector
achiev
highlevel
antigen
express
wang
et
al
efficaci
dna
vaccin
optim
antigen
gene
modifi
fulllength
gene
sequenc
candid
antigen
directli
use
antigen
gene
insert
dna
vaccin
may
requir
modif
order
achiev
highlevel
express
function
antigen
protein
exampl
hiv
dna
vaccin
effici
express
fulllength
glycoenvelop
protein
env
kda
protein
howev
two
truncat
version
env
protein
express
extracellular
portion
env
capabl
produc
larg
amount
env
antigen
elicit
high
envspecif
antibodi
respons
sometim
signal
peptid
sequenc
differ
natur
leader
sequenc
may
also
improv
antigen
express
immunogen
dna
vaccin
wang
et
al
process
modifi
origin
antigen
code
sequenc
call
antigen
engin
lu
et
al
rout
dna
vaccin
inocul
greatli
alter
immunogen
dna
vaccin
variou
method
deliv
dna
host
develop
use
variou
administr
method
without
adjuv
deliveri
methodolog
dna
vaccin
start
intramuscular
inject
socal
nake
dna
host
allow
uncoat
dna
taken
cell
transcrib
antigen
produc
final
immun
respons
elicit
develop
dna
vaccin
technolog
includ
facilit
dna
vaccin
employ
use
carrier
made
variou
chemic
materi
eg
lipid
polym
cation
poli
lactidecoglycolid
plg
microparticl
felgner
ringold
wheeler
et
al
stopeck
et
al
herrmann
et
al
klavinski
et
al
ohagan
et
al
otten
et
al
dna
vaccin
nake
formul
carrier
deliv
intraderm
intramuscularli
subcutan
convent
needl
inject
mucos
deliveri
dna
vaccin
also
test
includ
intranas
rout
howev
studi
emulsionmedi
techniqu
requir
order
induc
immun
kim
et
al
physic
deliveri
method
gene
gun
electropor
improv
effici
dna
vaccin
uptak
cell
andor
increas
activ
immun
system
signific
immun
respons
observ
small
mammal
use
tradit
rout
administr
ie
intramuscular
intraderm
needl
inject
inocul
method
proven
less
success
larger
anim
human
studi
hand
physic
deliveri
approach
use
particl
mediat
epiderm
deliveri
pmed
devic
proven
effect
elicit
immun
respons
human
hepat
b
viru
tacket
et
al
roy
et
al
rottinghau
et
al
influenza
drape
et
al
malaria
sinc
success
dna
vaccin
inocul
method
pmed
elicit
immun
respons
nonhuman
primat
human
commerci
avail
clinic
use
becom
import
util
techniqu
method
increas
immunogen
dna
vaccin
current
develop
one
method
primeboost
approach
rational
underli
strategi
genebas
vaccin
present
recombin
viral
vector
dna
plasmid
elicit
immun
respons
produc
antigen
vivo
howev
immun
respons
strong
particularli
human
order
increas
level
immun
respons
particular
cellmedi
immun
respons
strategi
develop
prime
immun
system
dna
vaccin
boost
recombin
viral
vector
pancholi
et
al
ramshaw
ramsay
mcshane
et
al
schneider
et
al
gonzalo
et
al
mellquistriemenschneid
et
al
woodland
seaman
et
al
wu
et
al
perkin
et
al
attenu
viru
yuan
et
al
dna
viral
vector
combin
proven
effect
elicit
highlevel
cellmedi
immun
infect
protein
go
constant
mutat
due
lack
proofread
function
retrovir
polymeras
structur
envelop
glycoprotein
env
immunodomin
antigen
complic
highli
variabl
escap
antibodi
respons
recombin
protein
vaccin
form
antigen
fail
protect
highrisk
popul
two
phase
iii
efficaci
trial
flynn
et
al
gilbert
et
al
pitisuttithum
et
al
live
attenu
vaccin
approach
success
simian
immunodefici
viru
siv
studi
nonhuman
primat
desrosi
et
al
daniel
et
al
due
safeti
concern
approach
littl
hope
test
human
hiv
among
first
pathogen
dna
vaccin
approach
explor
wang
et
al
lu
et
al
hiv
vaccin
field
quickli
becam
major
test
ground
optim
applic
dna
vaccin
dna
vaccin
use
express
mani
key
antigen
includ
env
gag
pol
nef
rev
tat
induct
antibodyand
cellmedi
immun
respons
current
dna
vaccin
one
key
compon
almost
everi
major
hiv
vaccin
develop
program
dna
vaccin
use
mainli
prime
immun
typic
combin
either
viral
vector
boost
mwau
et
al
graham
et
al
tavel
et
al
protein
boost
wang
et
al
human
studi
plan
ongo
result
studi
provid
import
guidanc
futur
develop
dna
vaccin
emerg
infecti
diseas
biodefens
applic
influenza
viru
infect
remain
major
health
threat
human
anim
influenza
virus
infect
human
anim
speci
includ
swine
hors
avian
predomin
human
influenza
viru
vaccin
trival
inactiv
influenza
vaccin
tiv
incorpor
predomin
virus
predict
circul
next
influenza
season
vaccin
typic
includ
subtyp
subtyp
influenza
plu
influenza
b
viru
immunogen
vaccin
rel
low
requir
annual
booster
immun
maintain
level
protect
immun
respons
develop
new
protect
antibodi
mutat
viral
antigen
occasion
emerg
newli
develop
coldadapt
live
influenza
viru
vaccin
much
improv
immunogen
respons
nonhuman
primat
studi
letvin
et
al
boyer
et
al
even
human
mwau
et
al
vuola
et
al
goonetillek
et
al
hank
et
al
altern
recombin
protein
also
use
boost
immun
system
prime
dna
vaccin
barnett
et
al
letvin
et
al
richmond
et
al
pal
et
al
pal
et
al
wang
et
al
wang
et
al
lu
law
et
al
dna
primeprotein
boost
combin
proven
effect
elicit
balanc
humor
cellmedi
immun
respons
even
human
studi
wang
et
al
dna
prime
protein
boost
compon
use
alon
shown
less
effect
induc
immun
respons
compar
prime
plu
boost
approach
wang
et
al
wang
et
al
larg
number
studi
use
variou
anim
model
conduct
past
year
examin
dna
vaccin
immunogen
wide
rang
pathogen
includ
virus
bacteria
parasit
contrari
popular
belief
dna
vaccin
complic
simpli
insert
randomli
select
pathogen
gene
dna
vaccin
vector
process
develop
success
dna
vaccin
differ
scientif
discoveri
trial
error
follow
section
result
select
dna
vaccin
studi
present
illustr
variou
aspect
develop
dna
vaccin
mani
import
biodefens
emerg
infecti
diseas
target
past
decad
acquir
immunodefici
syndrom
aid
number
one
emerg
infecti
diseas
centuri
continu
worldwid
pandem
new
millennium
develop
effect
aid
vaccin
proven
challeng
initi
anticip
appear
natur
adapt
immun
protect
infect
henc
correl
protect
induc
vaccin
uncertain
retroviru
integr
genom
host
divid
cell
turn
becom
sourc
continu
use
young
children
older
popul
due
lack
safeti
data
group
restrict
greatli
reduc
util
new
vaccin
young
children
older
peopl
particularli
vulner
influenza
infect
emerg
threat
avian
influenza
potenti
caus
futur
pandem
rais
issu
vaccin
efficaci
product
stockpil
old
influenza
vaccin
technolog
may
suffici
face
new
challeng
influenza
dna
vaccin
develop
anoth
earli
key
area
field
studi
demonstr
immunogen
dna
vaccin
use
either
nucleocapsid
np
hemagglutinin
ha
antigen
ulmer
et
al
robinson
et
al
fynan
et
al
landmark
studi
earli
show
dna
vaccin
express
np
effect
elicit
npspecif
ctl
protect
mice
subsequ
challeng
heterolog
strain
influenza
viru
measur
decreas
viral
lung
titer
inhibit
mass
loss
increas
surviv
ulmer
et
al
subsequ
studi
group
confirm
protect
immun
respons
induc
np
dna
vaccin
cox
et
al
combin
dna
primeadenovir
vector
boost
vaccin
epstein
et
al
also
report
show
np
dna
vaccin
alon
effect
protect
pig
challeng
homolog
viru
macklin
et
al
howev
later
studi
ferret
nonhuman
primat
demonstr
efficaci
dna
vaccin
encod
three
protein
np
ha
antigen
donnelli
et
al
donnelli
et
al
dna
vaccin
express
influenza
viral
antigen
also
report
includ
coexpress
antigen
okuda
et
al
codeliveri
np
dna
vaccin
plu
low
dose
haexpress
dna
vaccin
jimenez
et
al
use
naexpress
dna
vaccin
chen
et
al
chen
et
al
variou
level
protect
influenza
dna
vaccin
achiev
mous
model
protect
influenza
b
viru
infect
also
achiev
dna
vaccin
express
ha
na
antigen
nb
np
dna
vaccin
chen
et
al
haexpress
dna
vaccin
appear
protect
influenza
dna
vaccin
protect
elicit
ha
dna
vaccin
correl
titer
neutral
antibodi
robinson
et
al
howev
recent
studi
suggest
ha
antigen
serotyp
influenza
virus
requir
differ
antigen
design
induct
optim
protect
antibodi
respons
wang
et
al
may
affect
select
ha
antigen
avian
influenza
virus
ha
dna
vaccin
success
elicit
antibodi
respons
protect
sever
avian
influenza
virus
includ
kodih
et
al
kodih
et
al
jiang
et
al
qiu
et
al
ha
dna
vaccin
shown
induc
immun
protect
homolog
lethal
viru
also
two
antigen
variant
chicken
kodih
et
al
level
protect
may
vari
differ
anim
model
despit
success
induc
protect
immun
heterolog
viral
challeng
chicken
ha
dna
vaccin
encod
heterolog
virus
prevent
infect
mice
howev
ha
dna
vaccin
prevent
death
associ
infect
kodih
et
al
new
dna
vaccin
technolog
also
incorpor
design
improv
influenza
dna
vaccin
design
codon
optim
shown
improv
immunogen
protect
antibodi
respons
hi
microneutr
antibodi
ha
dna
vaccin
wang
et
al
jiang
et
al
consensusbas
dna
vaccin
avian
influenza
virus
produc
initi
result
show
possibl
induc
crossreact
cellular
immun
laddi
et
al
howev
whether
consensu
antigen
induc
protect
immun
respons
differ
virus
remain
unconfirm
one
key
contribut
influenza
dna
vaccin
research
demonstr
ha
dna
vaccin
could
induc
haspecif
antibodi
respons
induc
human
use
particlemedi
epiderm
deliveri
pmed
devic
group
healthi
adult
subject
receiv
singl
dose
g
ha
dna
vaccin
pmed
influenza
dna
vaccin
elicit
serum
hemagglutinationinhibit
antibodi
respons
three
dose
level
highest
consist
respons
subject
vaccin
highest
dose
day
sera
haspecif
antibodi
respons
g
group
reach
level
requir
influenza
vaccin
approv
establish
committe
proprietari
medic
product
cpmp
european
union
drape
et
al
result
import
demonstr
dna
vaccin
capabl
elicit
protect
immun
respons
level
one
notabl
factor
studi
use
gene
gun
deliveri
method
proven
effect
needl
inject
dna
vaccin
induc
immun
respons
human
avail
gene
gun
epiderm
deliveri
method
import
success
develop
dna
vaccin
biodefens
emerg
neglect
diseas
contrari
previou
studi
studi
observ
increas
antibodi
respons
vaccin
mice
rather
found
cellmedi
respons
correl
protect
dna
primeprotein
boost
studi
rhesu
macaqu
immun
fourantigen
formul
form
either
dna
vaccin
alon
escherichia
coli
produc
recombin
protein
vaccin
alon
combin
vaccin
anim
receiv
primeboost
immun
achiev
best
protect
heraud
et
al
dna
vaccin
approach
also
provid
uniqu
technic
advantag
develop
vaccin
close
relat
smallpox
antigen
permit
direct
clone
express
antigen
variola
major
sakhatskyy
et
al
aldazcarrol
et
al
sinc
protect
antigen
gene
chemic
synthes
even
codon
optim
without
directli
work
highli
pathogen
variola
major
virus
longer
avail
research
applic
summari
dna
vaccin
particularli
use
next
gener
smallpox
vaccin
base
subunit
antigen
deliv
multipl
protect
antigen
one
mix
formul
elicit
antibodyand
cellmedi
immun
respons
optim
antigen
sequenc
design
protect
antigen
optim
gene
also
use
produc
recombin
proteinbas
subunit
vaccin
sever
acut
respiratori
syndrom
sar
acut
respiratori
diseas
caus
newli
recogn
human
coronaviru
sarscov
first
report
asia
outbreak
approxim
peopl
worldwid
becam
ill
fatal
outbreak
final
contain
cdc
sar
first
major
emerg
infecti
diseas
centuri
although
final
human
vaccin
develop
sever
candid
antigen
discov
test
dna
vaccin
sar
infect
nucleocapsid
protein
n
envelop
spike
protein
examin
abil
induc
protect
immun
sarscov
mice
dna
plasmid
encod
n
protein
shown
effect
elicit
humor
cellular
immun
mice
two
three
immun
zhu
et
al
zhao
et
al
sinc
n
antigen
known
target
antibodymedi
protect
major
sarscov
dna
vaccin
incorpor
protein
key
protect
origin
smallpox
vaccin
base
vaccinia
viru
vacv
facilit
worldwid
erad
smallpox
last
case
natur
smallpox
infect
report
somalia
despit
elimin
natur
occur
smallpox
infect
threat
use
biolog
weapon
compel
enough
develop
vaccin
strategi
protect
larg
percentag
popul
longer
immun
diseas
poxvirus
larg
virus
genom
encod
protein
size
viru
complic
effort
delin
major
pa
furthermor
rel
import
humor
cellular
immun
vaccineinduc
protect
immun
uncertain
welldesign
anim
studi
dna
vaccin
approach
recent
identifi
sever
protect
pox
antigen
two
form
infecti
poxviru
intracellular
matur
viru
imv
extracellular
envelop
viru
eev
studi
shown
vaccinia
viru
imvspecif
antigen
eevspecif
antigen
immunogen
protect
albeit
variabl
vacv
infect
anim
model
galmich
et
al
hooper
et
al
hooper
et
al
fogg
et
al
pulford
et
al
sakhatskyy
et
al
sakhatskyy
et
al
xiao
et
al
antigen
induc
hightit
serum
antibodi
andor
neutral
antibodi
vaccinia
viru
galmich
et
al
hooper
et
al
hooper
et
al
hooper
et
al
hooper
et
al
heraud
et
al
sakhatskyy
et
al
sakhatskyy
et
al
fourgen
combin
dna
vaccin
encod
two
imv
two
eev
antigen
protect
vacv
challeng
mice
monkeypox
viru
challeng
nonhuman
primat
hooper
et
al
separ
studi
imv
antigen
shown
highli
immunogen
antigen
induc
highlevel
protect
alon
combin
pox
antigen
sakhatskyy
et
al
sakhatskyy
et
al
howev
pox
dna
vaccin
well
recombin
proteinbas
pox
subunit
vaccin
protect
liveattenu
vaccinia
viru
vaccin
unless
polyval
formul
andor
multipl
immun
use
hooper
et
al
hooper
et
al
fogg
et
al
pulford
et
al
sakhatskyy
et
al
sakhatskyy
et
al
limit
studi
measur
cellmedi
immun
respons
follow
immun
variou
dna
vaccin
vacv
challeng
otero
et
al
recent
studi
demonstr
mice
immun
dna
plasmid
encod
antigen
vacv
elicit
strong
eevinduc
respons
pulford
et
al
interestingli
antigen
matter
whether
entir
protein
fragment
protein
incorpor
dna
vector
immun
signific
level
sspecif
immun
respons
elicit
includ
hightit
bind
antibodi
kong
et
al
zakhartchouk
et
al
huang
et
al
zhao
et
al
hu
et
al
wang
et
al
neutral
antibodi
respons
woo
et
al
zakhartchouk
et
al
wang
et
al
addit
sspecif
cellular
immun
respons
includ
cell
respons
detect
dna
vaccin
huang
et
al
zhao
et
al
hu
et
al
even
greater
level
immun
observ
dna
vaccin
includ
part
primeboost
regimen
woo
et
al
zakhartchouk
et
al
cytokin
includ
molecular
adjuv
hu
et
al
although
possibl
determin
efficaci
sar
dna
vaccin
due
limit
avail
anim
test
facil
capabl
work
sarscov
shown
dna
vaccin
ie
delet
transmembran
domain
truncat
cytoplasm
domain
effect
significantli
reduc
viral
load
lung
infect
mice
howev
limit
sarscov
mous
model
lack
clinic
endpoint
eg
diseas
death
field
limit
lack
gener
accept
nonhuman
primat
model
result
promis
develop
dna
vaccin
sarscov
howev
studi
need
use
better
anim
model
assess
abil
experiment
vaccin
protect
infect
diseas
import
note
use
dna
vaccin
platform
prove
nimbl
facilit
rapid
develop
highli
immunogen
candid
vaccin
sudden
emerg
new
human
infecti
diseas
infect
either
ebola
marburg
typic
result
sever
hemorrhag
fever
human
nonhuman
primat
four
speci
ebola
identifi
ie
zair
sudan
reston
ivori
coast
first
known
case
occur
zair
marburg
viru
identifi
name
site
infect
occur
marburg
germani
effect
prophylaxi
treatment
infect
either
viru
filovirus
uncommon
caus
human
infect
develop
filoviru
vaccin
warrant
base
remark
lethal
mortal
rate
rang
marburg
ebola
limit
work
develop
live
attenu
ebola
viru
vaccin
safeti
issu
make
approach
somewhat
problemat
signific
progress
made
develop
dna
vaccin
ebola
marburg
virus
includ
complet
recent
phase
human
trial
ebola
dna
vaccin
vaccin
strategi
target
variou
viral
protein
includ
secret
sgp
transmembran
gp
form
glycoprotein
nucleoprotein
np
dna
vaccin
test
variou
anim
model
includ
mice
guinea
pig
nonhuman
primat
human
promis
immunogen
result
earli
studi
three
viral
protein
test
determin
immunogen
mice
protect
efficaci
guinea
pig
xu
et
al
three
g
inject
np
sgp
dna
plasmid
effect
although
vari
level
elicit
antibodi
respons
gp
dna
elicit
neutral
respons
howev
np
construct
induc
minim
ctl
respons
wherea
sgp
gp
plasmid
induc
strong
ctl
respons
furthermor
guinea
pig
challeng
approxim
month
first
immun
show
nearli
complet
protect
gp
sgp
np
similar
result
observ
mous
protect
studi
gp
protein
although
mani
four
immun
requir
vanderzanden
et
al
riemenschneid
et
al
likewis
gp
dna
primerecombin
baculovirusderiv
gp
protein
boost
regimen
afford
guinea
pig
good
protect
separ
studi
show
dna
immun
subsequ
boost
adenoviru
vector
encod
either
gp
np
combin
two
confer
protect
guinea
pig
sullivan
et
al
furthermor
antibodi
titer
increas
mice
receiv
gp
dna
prime
plu
adenoviru
vector
boost
compar
dna
alon
sinc
ebola
viru
modifi
order
produc
diseas
rodent
primat
model
infect
would
close
emul
infect
human
three
inject
nake
gp
dna
vaccin
sever
month
rest
recombin
adenoviru
base
vaccin
boost
antibodi
titer
increas
compar
dna
immun
alon
increas
cellular
immun
respons
appear
driven
cell
vaccin
regimen
abl
confer
protect
four
four
monkey
steril
immun
observ
three
four
recent
phase
clinic
trial
conduct
determin
safeti
immunogen
dna
vaccin
ebola
viru
healthi
volunt
veterinari
vaccin
exist
wnv
time
initi
outbreak
differ
version
dna
vaccin
develop
show
good
immunogen
one
version
express
wnv
capsid
protein
vivo
studi
mice
show
type
immun
respons
immun
anim
yang
et
al
anoth
use
novel
approach
express
fulllength
infecti
kunjin
viru
rna
kunjin
viru
genet
stabl
australian
flaviviru
origin
shown
genet
antigen
close
relat
sever
wnv
strain
later
reclassifi
wnv
heinz
et
al
sequenc
analysi
reveal
amino
acid
homolog
kunjin
wnv
caus
initi
new
york
outbreak
use
modifi
molecular
clone
mutat
gene
attenu
kunjin
strain
produc
use
vaccin
use
dna
vaccin
direct
vivo
transcript
fulllength
attenu
infecti
kun
viral
rna
mice
led
full
protect
wnv
ny
strain
hall
et
al
scientist
us
cdc
fort
dodg
laboratori
inc
divis
wyeth
develop
pcbwn
dna
vaccin
express
wnv
prm
e
protein
davi
et
al
singl
intramuscular
inject
pcbwn
dna
vaccin
induc
protect
immun
prevent
wnv
infect
mice
hors
davi
et
al
vaccin
licens
us
depart
agricultur
juli
becom
first
dna
vaccin
approv
regulatori
agenc
grant
full
licensur
usda
center
veterinari
biolog
determin
vaccin
safeti
efficaci
satisfactorili
demonstr
april
dna
vaccin
target
wnv
develop
scientist
nih
vaccin
research
center
vrc
collabor
vical
inc
enter
phase
clinic
trial
target
complet
date
octob
nih
experiment
vaccin
encod
two
key
wnv
surfac
protein
precursor
transmembran
prm
protein
envelop
e
protein
vaccin
administ
via
biojector
devic
particip
receiv
three
inject
im
ml
vaccin
per
immun
total
ml
studi
day
primari
studi
endpoint
vaccin
safeti
secondari
immunogen
endpoint
includ
elisa
neutral
antibodi
respons
elispot
ic
stain
assay
wnvspecif
cell
respons
result
phase
clinic
trial
yet
avail
martin
et
al
press
viral
encephalitid
particular
japanes
enceph
je
dna
vaccin
contain
three
plasmid
equal
concentr
np
zair
strain
two
gp
one
zair
strain
sudangulu
strain
vaccin
formul
safe
well
toler
dna
vaccin
formul
elicit
antigenspecif
antibodi
respons
least
one
three
antigen
vaccine
vaccin
show
antibodi
respons
either
gp
antigen
one
time
point
vaccin
schedul
similar
observ
monkey
sullivan
et
al
cell
respons
robust
respons
gp
antigen
produc
greatest
respons
compar
np
dna
vaccin
platform
also
use
develop
vaccin
marburg
viru
although
studi
conduct
date
marburg
viru
gpexpress
dna
vaccin
administ
guinea
pig
serum
antibodi
detect
three
immun
vaccin
prevent
death
anim
exhibit
higher
increas
antimarburg
viru
antibodi
month
infect
howev
combin
dna
prime
plu
baculovirusexpress
recombin
gp
boost
adjuv
one
dna
prime
two
protein
boost
confer
complet
protect
wherea
neither
vaccin
modal
administ
alon
hevey
et
al
second
studi
observ
complet
protect
guinea
pig
protect
two
three
monkey
vaccin
marburg
viru
gp
dna
plasmid
antibodi
respons
observ
two
monkey
surviv
challeng
significantli
differ
monkey
surviv
indic
antibodi
level
alon
necessarili
predict
protect
marburg
infect
result
filoviru
vaccin
studi
promis
indic
vaccin
relat
dna
vaccin
encod
variou
ebola
marburg
antigen
induc
cellular
humor
immun
respons
vaccin
confer
level
protect
infect
human
trial
determin
efficaci
vaccin
west
nile
viru
end
summer
outbreak
viral
enceph
new
york
citi
surround
area
later
determin
caus
west
nile
viru
wnv
outbreak
continu
subsequ
year
unit
state
human
hors
human
tickborn
enceph
tbe
transmit
human
anim
infect
mosquito
tick
infect
virus
result
variou
symptom
rang
fever
enceph
inactiv
vaccin
infect
immun
regimen
requir
multipl
dose
without
produc
longterm
immun
repeat
immun
increas
cost
vaccin
campaign
develop
countri
inactiv
vaccin
licens
unit
state
effort
made
util
dna
vaccin
technolog
order
produc
vaccin
encephalitid
improv
efficaci
greater
eas
lower
cost
product
administr
je
viru
wide
distribut
throughout
asia
caus
diseas
human
central
nervou
system
three
viral
protein
report
provid
protect
immun
prm
e
dna
vaccin
encod
viral
protein
success
induc
antibodi
protect
je
mous
model
one
report
dna
vaccin
shown
afford
greater
protect
je
challeng
induc
higher
level
antibodi
compar
dna
vaccin
encod
e
prm
protein
lin
et
al
anoth
studi
found
construct
encod
prm
e
produc
neutral
antibodi
protect
mice
je
challeng
construct
encod
capsid
c
nonstructur
protein
induc
cytotox
lymphocyt
respons
afford
partial
protect
je
challeng
konishi
et
al
result
interpret
indic
rel
import
antibodi
vi
cell
vaccineinduc
protect
investig
report
dna
vaccin
encod
e
prm
protein
effect
elicit
better
respons
compar
commerci
avail
je
vaccin
jevax
chang
et
al
addit
studi
shown
needlefre
injector
administr
dna
vaccin
encod
e
prm
protein
elicit
increas
neutral
antibodi
earlier
compar
intramuscular
administr
monkey
tanabayashi
et
al
mous
konishi
et
al
konishi
et
al
primeboost
regimen
proven
superior
method
maxim
vaccin
immunogen
two
studi
show
boost
eprm
dna
vaccin
formul
either
subvir
extracellular
particl
imoto
konishi
inactiv
commerci
avail
jevax
konishi
et
al
konishi
et
al
superior
either
vaccin
modal
alon
induc
neutral
antibodi
dna
primejevax
boost
regimen
induc
longlast
immun
titer
still
week
follow
last
immun
imoto
konishi
furthermor
dna
vaccin
encod
prme
viral
protein
afford
greater
cross
protect
heterolog
je
viral
strain
compar
inactiv
viru
vaccin
wu
et
al
tbe
frequent
caus
russian
spring
summer
enceph
rsse
central
european
enceph
cee
dna
vaccin
develop
tbe
success
anim
model
elicit
protect
immun
respons
viral
challeng
flavivirus
effect
vaccin
encod
prm
e
gene
dna
vaccin
express
prm
e
gene
rsse
cee
deliv
gene
gun
shown
protect
mice
monkey
schmaljohn
et
al
homolog
heterolog
viral
challeng
induc
longlast
neutral
antibodi
respons
protect
appear
mediat
neutral
antibodi
base
passiv
transfer
studi
mice
use
high
neutral
titer
antibodi
gener
monkey
rsse
cee
dna
immun
schmaljohn
et
al
current
approv
vaccin
dengu
virus
den
virus
spread
aed
aegypti
mosquito
endem
throughout
tropic
subtrop
region
world
approxim
million
infect
per
year
result
dengu
fever
seriou
dengu
hemorrhag
fever
dhf
although
variou
vaccin
approach
includ
live
attenu
inactiv
whole
virion
recombin
proteinbas
subunit
vaccin
test
presenc
four
serotyp
den
complic
immunopatholog
mechan
involv
dhf
greatli
reduc
speed
develop
effect
den
vaccin
sever
dna
vaccin
formul
develop
four
serotyp
case
tetraval
formul
induc
memori
immun
respons
homolog
heterolog
viral
challeng
konishi
et
al
typic
dna
vaccin
effect
elicit
humor
cellmedi
immun
respons
contain
den
premembranemembran
prm
envelop
e
gene
immun
plasmid
encod
gene
shown
engend
antigenspecif
antibodi
neutral
antibodi
respons
protect
mice
raviprakash
et
al
konishi
et
al
konishi
et
al
nonhuman
primat
raviprakash
et
al
mice
konishi
et
al
konishi
et
al
konishi
et
al
putnak
et
al
nonhuman
challeng
lethal
dose
one
three
strain
wee
furthermor
immun
mice
show
strong
tcell
prolifer
respons
purifi
protein
partial
respons
compar
control
nagata
et
al
dna
vaccin
also
develop
vee
studi
replicationdefect
adenoviru
use
boost
immun
respons
follow
deliveri
dna
vaccin
express
region
encod
structur
protein
perkin
et
al
follow
dna
immun
differ
observ
vee
virusspecif
igg
respons
howev
follow
one
intranas
boost
homolog
adbas
vaccin
signific
increas
vee
virusspecif
igg
observ
primeboost
strategi
also
significantli
enhanc
protect
aerosol
vee
challeng
infect
rabi
viru
caus
acut
enceph
extrem
high
fatal
rate
inactiv
liveattenu
human
rabi
vaccin
exist
limit
dna
vaccin
proven
success
rabi
infect
variou
anim
model
first
seri
studi
mice
immun
rabi
glycoprotein
display
rabi
viru
glycoproteinspecif
cellmedi
humor
immun
respons
addit
complet
protect
viral
challeng
xiang
et
al
xiang
et
al
subsequ
studi
show
dna
vaccin
encod
rabi
glycoprotein
induc
increas
geometr
mean
neutral
antibodi
titer
follow
boost
day
primari
immun
nonhuman
primat
lodmel
et
al
lodmel
et
al
addit
studi
group
show
gene
gun
administr
afford
mice
protect
rabi
viru
challeng
protect
level
antibodi
persist
day
lodmel
et
al
lodmel
et
al
also
show
differ
primeboost
regimen
elicit
vari
level
neutral
antibodi
respons
prime
dna
vaccin
recombin
vaccinia
viru
vaccin
rvv
commerci
avail
inactiv
rabi
vaccin
follow
boost
either
dna
inactiv
vaccin
result
rapid
longlast
antibodi
respons
lodmel
ewalt
group
also
demonstr
dna
vaccin
could
use
effect
postexposur
vaccin
lodmel
ewalt
lodmel
et
al
arenavirus
famili
virus
usual
transmit
rodent
human
primat
putnak
et
al
addit
studi
examin
abil
tetraval
dna
vaccin
formul
encod
prm
e
gene
four
dengu
serotyp
induc
immun
respons
found
antibodi
specif
serotyp
could
induc
follow
immun
mota
et
al
apt
et
al
konishi
et
al
raviprakash
et
al
furthermor
immun
tetraval
dna
vaccin
abl
elicit
neutral
antibodi
respons
day
follow
viral
challeng
homolog
viru
use
challeng
assay
heterolog
virus
ie
use
challeng
konishi
et
al
abil
dengu
viru
nonstructur
protein
elicit
immun
respons
also
examin
contradictori
result
one
studi
dna
vaccin
encod
fail
induc
antigenspecif
antibodi
one
three
immun
howev
greater
respons
observ
follow
challeng
vaccin
mice
compar
unvaccin
group
wu
et
al
contrast
mice
vaccin
dna
vaccin
base
protein
display
high
level
antibodi
costa
et
al
appear
though
two
dna
vaccin
encod
antigen
viru
slight
differ
immun
schedul
andor
dose
may
led
differ
result
despit
fact
antibodi
detect
one
three
immun
wu
et
al
dna
vaccin
confer
protect
lethal
challeng
studi
furthermor
newborn
mice
born
dam
either
infect
viru
litter
immun
dna
vaccin
litter
also
protect
dengu
viru
follow
challeng
wu
et
al
equin
encephalitid
includ
venezuelan
equin
enceph
vee
western
equin
enceph
wee
mosquitoborn
virus
transmit
bird
hors
human
clinic
find
infect
rang
mild
flulik
symptom
enceph
coma
death
equin
vaccin
virus
develop
human
vaccin
current
avail
dna
vaccin
technolog
use
develop
vaccin
vee
wee
particular
import
virus
potenti
use
biolog
warfar
agent
first
studi
dna
immun
plasmid
encod
major
structur
protein
wee
capsid
afford
protect
mice
includ
virus
lymphocyt
choriomening
lcm
lassa
viru
junin
viru
machupo
viru
infect
virus
present
wide
rang
symptom
includ
fever
flulik
symptom
mening
enceph
sever
fatal
hemorrhag
fever
studi
conduct
develop
dna
vaccin
viral
agent
one
studi
singl
immun
dna
plasmid
encod
fulllength
lassa
nucleoprotein
abl
induc
cell
respons
mice
afford
protect
two
arenavirus
lcmv
pichind
viru
rodriguezcarreno
et
al
unfortun
dna
immun
lcmv
anoth
studi
show
favor
result
follow
intracrani
viral
challeng
vaccin
mice
afford
protect
viral
challeng
also
display
greater
immunopatholog
instead
evidenc
clinic
symptom
enceph
eventu
death
zarozinski
et
al
studi
repres
rare
exampl
dna
vaccin
may
worsen
outcom
viral
infect
although
believ
unexpect
result
part
uniqu
immunopathogenesi
lcmv
infect
care
select
pa
may
also
import
develop
dna
vaccin
anthrax
one
earli
model
pathogen
use
assess
feasibl
appli
dna
vaccin
technolog
develop
vaccin
bacteri
infect
earli
day
dna
vaccin
research
mani
consid
dna
vaccin
use
tool
induct
cellmedi
immun
respons
appreci
potenti
dna
vaccin
induc
highqual
protect
antibodi
respons
antibodi
play
central
role
control
bacteri
infect
initi
limit
dna
vaccin
studi
bacteri
agent
detail
analysi
dna
vaccin
anthrax
provid
import
mileston
area
anthrax
infect
caus
baccillu
anthraci
diseas
high
mortal
attract
great
attent
unit
state
follow
intent
releas
agent
although
licens
vaccin
anthrax
develop
bioport
corpor
lans
mi
multipl
immun
requir
order
maintain
protect
level
immun
safeti
previou
manufactur
process
issu
first
studi
establish
possibl
use
dna
vaccin
induc
protect
immun
respons
anthrax
gu
et
al
develop
dna
vaccin
contain
portion
protect
antigen
pa
protein
respons
initi
bind
bacteria
target
cell
antibodi
pa
confirm
protect
guinea
pig
rabbit
anthrax
challeng
littl
et
al
kobil
et
al
riemenschneid
et
al
moham
et
al
multipl
inocul
paexpress
dna
plasmid
antipa
igg
antibodi
observ
immun
mice
level
increas
subsequ
boost
use
vitro
neutral
assay
studi
show
pool
serum
twiceboost
immun
mice
protect
anthrax
dilut
protect
observ
dilut
vivo
protect
assay
author
found
mice
immun
plasmid
pa
dna
complet
protect
challeng
control
mice
surviv
subsequ
studi
show
plasmid
dna
prime
encod
pa
antigen
follow
recombin
protein
rpa
boost
significantli
increas
antibodi
level
protect
efficaci
anthrax
challeng
mice
williamson
et
al
rabbit
howev
increas
antibodi
titer
protect
efficaci
also
observ
rabbit
without
recombin
protein
boost
dna
alon
effect
longlast
hermanson
et
al
examin
passiv
immunotherapi
anthrax
infect
rabbit
immun
codonoptim
plasmid
dna
vaccin
encod
pa
effect
immun
strategi
twice
dna
prime
one
time
protein
boost
regimen
immun
rabbit
sera
shown
contain
elisa
neutral
antibodi
transfer
mice
either
h
prior
h
lethal
anthrax
challeng
mice
receiv
hyperimmun
rabbit
sera
h
prior
anthrax
challeng
surviv
day
challeng
end
observ
period
mice
receiv
sera
h
challeng
one
mice
die
day
challeng
indic
protect
anthrax
could
achiev
passiv
administr
antibodi
result
dna
immun
herrmann
et
al
togeth
studi
indic
dna
immun
effect
produc
hightit
antibodi
respons
confer
protect
aerosol
anthrax
challeng
mice
rabbit
yersinia
pesti
pesti
caus
agent
plagu
endem
mani
rodent
popul
throughout
world
great
concern
due
pesti
result
show
although
fulllength
form
antigen
poor
immunogen
one
alter
plasmid
particular
contain
code
sequenc
protein
acid
long
sequenc
code
put
bacteri
signal
peptid
miss
induc
substanti
antibodi
titer
protect
immun
mice
subcutan
pesti
challeng
determin
mice
receiv
gene
gun
inocul
protect
ld
pesti
challeng
anim
surviv
challeng
use
dna
vaccin
technolog
group
nd
line
antigen
pesti
studi
abil
elicit
protect
antibodi
respons
wang
et
al
pesti
outer
protein
yopb
yopd
yopo
plasminogen
activ
proteas
pla
yop
secret
protein
f
yscf
necessari
full
virul
pesti
propos
potenti
pa
vaccin
dna
immun
use
tool
studi
rel
protect
immun
individu
antigen
standard
intranas
challeng
system
balbc
mice
natur
fulllength
gene
sequenc
pesti
protein
display
good
level
protein
express
vitro
deliv
dna
vaccin
vector
mammalian
cell
result
overal
immunogen
wildtyp
gene
dna
vaccin
low
elicit
antigenspecif
antibodi
respons
howev
gene
sequenc
modif
includ
remov
hydrophob
region
addit
signal
peptid
sequenc
high
secret
potenti
significantli
improv
level
protein
express
well
immunogen
antigen
elicit
highlevel
antigenspecif
antibodi
respons
mice
modifi
yopd
yopo
yscf
antigen
abl
protect
immun
mice
vari
degre
lethal
challeng
pesti
kim
strain
cfu
intranas
inocul
protect
observ
either
yopb
pla
antigen
wang
et
al
result
studi
demonstr
dna
immun
use
screen
optim
compar
antigen
design
immunogen
candid
antigen
develop
subunitbas
plagu
vaccin
approach
use
expand
search
addit
protect
antigen
highli
virul
pesti
infect
result
studi
indic
protect
subcutan
intranas
plagu
indic
bubon
pneumon
plagu
respect
confer
administr
dna
vaccin
encod
differ
pesti
antigen
develop
broadli
activ
vaccin
plagu
import
defend
ill
use
potenti
biolog
weapon
plagu
transmit
flea
bite
caus
bubon
plagu
aerosol
caus
pneumon
plagu
pneumon
plagu
greatest
concern
biodefens
form
diseas
progress
rapidli
highli
transmiss
requir
therapi
shortli
infect
without
earli
intervent
pneumon
plagu
infect
certainli
fatal
featur
pneumon
plagu
along
possibl
use
biolog
weapon
present
strong
argument
develop
effect
vaccin
current
known
effect
clinic
vaccin
pneumon
plagu
varieti
wholecel
kill
plagu
vaccin
develop
efficaci
protect
pneumon
plagu
limit
small
anim
model
williamson
et
al
dna
vaccin
technolog
offer
advantag
establish
safe
effect
platform
protect
varieti
plagu
antigen
achiev
first
studi
compar
two
dna
vaccin
deliveri
method
ie
gene
gun
deliveri
g
plasmid
dna
versu
intramuscular
intraderm
deliveri
g
plasmid
dna
administr
plasmid
dna
encod
v
antigen
pesti
antibodi
respons
obtain
day
post
vaccin
observ
vaccin
group
howev
highest
geometr
mean
titer
observ
mice
vaccin
g
dna
via
gene
gun
least
effect
intraderm
administr
g
dna
bennett
et
al
littl
protect
afford
mice
inocul
im
gene
gun
optim
v
antigenexpress
dna
vaccin
addit
cmv
promot
two
six
mice
gene
gun
surviv
subcutan
challeng
pesti
greater
success
achiev
mice
administ
dna
vaccin
modifi
v
antigen
lcrv
use
human
tissu
plasminogen
activ
tpa
signal
sequenc
wang
et
al
studi
strong
v
antigenspecif
antibodi
elicit
mice
also
protect
intranas
challeng
pesti
particular
import
model
reflect
infect
deadli
mucos
challeng
plagu
tpav
dna
vaccin
abl
induc
excel
secret
v
antigen
oligomer
form
hypothes
import
elicit
protect
antibodi
respons
addit
v
antigen
immun
capsular
protein
shown
afford
protect
plagu
dna
vaccin
report
effect
elicit
protect
grosfeld
et
al
compar
three
dna
vaccin
carri
differ
signal
cellular
local
abil
induc
antibodi
protect
pathogen
biolog
weapon
without
intent
modif
antigen
escap
protect
elicit
origin
vaccin
botul
rare
seriou
paralyt
diseas
caus
bacterium
clostridium
botulinum
histor
three
natur
form
botul
exist
foodborn
wound
infant
howev
also
exit
manmad
inhal
form
botul
lethal
microgram
dose
rang
henc
repres
highli
danger
potenti
biothreat
seven
type
noncrossreact
botulinum
neurotoxin
exist
g
licens
trival
antitoxin
avail
cdc
contain
neutral
antibodi
type
b
e
treatment
botul
toxin
poison
cdc
addit
investig
heptaval
antitoxin
shown
effect
known
strain
botul
heptaval
formul
contract
strateg
nation
stockpil
begin
hh
howev
shown
strain
botul
capabl
produc
mixtur
two
toxin
type
cordoba
et
al
also
known
subtyp
serotyp
indic
understand
cross
protect
develop
appropri
vaccin
strategi
remain
great
challeng
studi
examin
feasibl
use
dna
vaccin
protect
botul
earli
studi
mice
immun
dna
vaccin
express
carboxyl
termin
kda
fragment
type
toxin
place
two
design
construct
lead
mhc
present
lead
mhc
ii
present
clayton
middlebrook
challeng
botulinum
serotyp
crossprotect
studi
serotyp
b
e
observ
construct
ineffect
induc
protect
challeng
botul
serotyp
ld
howev
mice
receiv
construct
least
g
dna
afford
level
protect
challeng
week
g
dna
increas
rate
surviv
challeng
serotyp
ld
minimum
week
pass
prior
challeng
protect
afford
challeng
present
week
immun
furthermor
result
show
cross
protect
afford
dna
immun
serotyp
b
e
none
anim
surviv
challeng
addit
studi
show
dna
vaccin
botulinium
subtyp
f
rare
form
botul
found
protect
mice
lethal
challeng
serotyp
bennett
et
al
jathoul
et
al
first
studi
group
minimum
three
im
inject
f
subtypespecif
dna
vaccin
contain
signal
sequenc
hc
domain
given
period
suffici
protect
mice
mld
botulinium
toxin
subtyp
f
singl
dose
protect
mice
challeng
less
day
vaccin
bennett
et
al
addit
result
studi
indic
relationship
may
exist
fhcspecif
antibodi
level
surviv
challeng
assay
dna
primeprotein
boost
regimen
induc
greater
level
serum
antibodi
compar
dna
alon
protein
alon
base
find
dna
vaccin
appear
use
design
optim
futur
botulinum
vaccin
protect
multipl
serotyp
toxin
gastriti
peptic
ulcer
gastric
cancer
link
infect
helicobact
pylori
bacterium
two
studi
examin
possibl
use
dna
vaccin
technolog
induc
antibodi
protect
h
pylori
infect
studi
success
todoroki
et
al
miyashita
et
al
differ
studi
dna
vaccin
encod
antigen
enzym
catalas
heat
shock
protein
b
hspa
hspb
respect
dna
vaccin
formul
induc
hightit
serum
antibodi
compar
empti
dna
vector
control
dna
vaccin
encod
catalas
serum
antibodi
level
detect
begin
week
final
immun
peak
level
month
post
immun
addit
analys
includ
measur
bacteri
colon
stomach
challeng
h
pylori
three
dna
vaccin
formul
catalas
hspa
hspb
afford
protect
h
pylori
replic
result
support
potenti
use
dna
vaccin
protect
h
pylori
infect
antibioticresist
strain
bacterium
develop
greater
need
develop
h
pylori
vaccin
mycobacterium
tuberculosi
tb
vaccin
bacil
calmetteguerin
bcg
wide
use
outsid
unit
state
set
high
tb
preval
unfortun
bcg
complet
effect
prevent
tb
infect
complic
interpret
tuberculin
skin
test
prevent
dna
vaccin
also
develop
target
tb
antigen
includ
tascon
et
al
ferraz
et
al
lowri
et
al
ferraz
et
al
alanin
prolinerich
antigen
apa
ferraz
et
al
katg
antigen
either
alon
variou
combin
morri
et
al
repiqu
et
al
cai
et
al
cai
et
al
high
level
specif
igg
antibodi
observ
mice
immun
individu
dna
vaccin
cai
et
al
construct
encod
antigen
cai
et
al
protect
tb
challeng
individu
dna
vaccin
encod
antigen
provid
partial
protect
tb
challeng
multival
katg
dna
vaccin
produc
antigenspecif
cellmedi
humor
immun
respons
stronger
protect
respons
tb
challeng
compar
current
bcg
vaccin
morri
et
al
studi
examin
efficaci
dna
vaccin
encod
heat
shock
protein
tuberculosi
found
protein
abl
decreas
number
live
bacteria
spleen
lung
infect
mice
one
dose
dna
vaccin
lower
effect
observ
dna
vaccin
formul
lowri
et
al
malaria
transmit
mosquito
remain
major
global
public
health
problem
year
million
new
case
malaria
occur
throughout
world
approxim
million
death
occur
mostli
children
subsaharan
africa
although
antimalari
drug
effect
prevent
treatment
malaria
infect
develop
vaccin
continu
ultim
goal
malaria
control
signific
develop
made
clinic
trial
test
variou
design
dna
vaccin
malaria
first
set
human
dna
vaccin
studi
plasmid
dna
vaccin
encod
plasmodium
falciparum
circumsporozoit
protein
pfcsp
produc
low
cmi
respons
human
volunt
even
use
pmed
wang
et
al
high
dna
dose
g
per
immun
effect
increas
posit
respons
antigenspecif
ctl
respons
observ
measur
antibodi
respons
detect
volunt
receiv
safe
welltoler
malaria
dna
emerg
extens
drugresist
tb
strain
despit
shortcom
bcg
like
continu
use
afflict
countri
reduc
mortal
rate
seriou
form
childhood
tb
eg
dissemin
mening
tb
acet
clear
effect
tb
vaccin
need
numer
studi
explor
potenti
use
dna
vaccin
technolog
facilit
develop
new
effect
vaccin
major
tb
dna
vaccin
studi
focus
famili
three
protein
complex
ag
complex
antigen
prime
target
found
cell
surfac
also
secret
bacterium
wiker
harbo
initi
studi
examin
immunogen
dna
vaccin
encod
three
form
complex
b
c
observ
hightit
antibodi
respons
immun
mice
subsequ
studi
show
secret
form
induc
higher
level
serum
antibodi
lower
dna
dose
confer
protect
highli
virul
strain
tuberculosi
compar
matur
form
protein
baldwin
et
al
dna
vaccin
encod
protein
induc
strong
respons
eg
increas
level
toward
nativ
protein
loze
et
al
broader
cell
respons
observ
natur
tuberculosi
infect
increas
mediat
cytotox
deni
et
al
addit
cellular
immun
respons
protect
challeng
confer
dna
vaccin
encod
protein
mice
loze
et
al
deni
et
al
guinea
pig
intramuscular
inject
baldwin
et
al
gene
gun
inocul
sugawara
et
al
protein
mice
loze
et
al
addit
studi
util
variou
primeboost
strategi
increas
immunogen
protect
efficaci
dna
vaccin
one
studi
prime
dna
vaccin
encod
protein
subsequ
boost
purifi
protein
primeboost
strategi
increas
respons
increas
produc
cell
increas
isotyp
antibodi
respons
increas
efficaci
dna
vaccin
tuberculosi
challeng
tangh
et
al
second
studi
examin
effect
dna
prime
subsequ
boost
current
tb
vaccin
bcg
found
dna
bcg
regimen
effect
bcg
alon
protect
tb
challeng
feng
et
al
ferraz
et
al
cell
deplet
attenu
protect
feng
et
al
vaccin
later
studi
dna
primerecombin
vaccinia
viru
ankara
mva
boost
approach
develop
enhanc
immunogen
malaria
dna
vaccin
recent
review
see
uniqu
chimer
antigen
metrap
produc
express
thrombospondin
relat
adhes
protein
trap
coupl
string
multipl
epitop
tcell
epitop
bcell
epitop
variou
preerythrocyt
p
falciparum
antigen
dna
immun
elicit
lowlevel
tcell
respons
amplifi
boost
mva
metrap
significantli
intramuscular
dna
prime
effect
gene
gunmedi
prime
combin
mva
boost
combin
immun
regimen
produc
partial
protect
manifest
delay
parasitemia
sporozoit
challeng
differ
strain
p
falciparum
recent
studi
demonstr
dna
primemva
boost
vaccin
encod
trap
produc
stronger
ex
vivo
elispot
respons
similar
dna
primemva
boost
vaccin
encod
circumsporozoit
cs
antigen
importantli
latter
vaccin
could
protect
healthi
malariana
adult
p
falciparum
sporozoit
challeng
trapexpress
dna
primemva
boost
vaccin
dunachi
et
al
differ
type
malaria
vaccin
primeboost
approach
test
human
combin
pfcsp
dna
vaccin
prime
boost
known
protect
recombin
protein
rt
fusion
protein
p
falciparum
pfcsp
protein
hepat
b
viru
surfac
antigen
hbsag
construct
encod
sever
tcell
epitop
administ
volunt
receiv
dna
vaccin
prime
earlier
trial
le
et
al
na
volunt
volunt
prime
pfcsp
dna
vaccin
protect
tcell
antibodi
respons
effect
protein
boost
addit
previous
observ
ctl
respons
effect
dna
prime
na
volunt
group
exhibit
antibodi
tcell
respons
tcell
respons
epstein
et
al
wang
et
al
find
suggest
pfcsp
dna
vaccin
effect
induct
antibodi
respons
either
alon
prime
vaccin
attempt
expand
breadth
protect
immun
respons
volunt
immun
mixtur
five
malaria
dna
vaccin
express
differ
p
falciparum
preerythrocyt
stage
antigen
conjunct
adjuv
plasmid
encod
human
granulocyt
macrophag
colonystimul
factor
hgmgsf
wang
et
al
respons
detect
multipl
class
andor
class
ii
restrict
tcell
epitop
five
antigen
csp
statist
differ
group
addit
analys
reveal
volunt
receiv
dna
alon
ie
without
hgmcsf
respons
class
class
ii
peptid
boost
challeng
p
falciparum
parasit
respons
class
ii
peptid
boost
volunt
vaccin
dna
hgmgsf
volunt
receiv
hgmcsf
actual
reduc
frequenc
respons
class
peptid
importantli
none
protect
malaria
challeng
rais
issu
antigen
select
sinc
previou
studi
demonstr
dna
primemva
boost
vaccin
express
metrap
antigen
abl
induc
partial
protect
tremend
stride
made
last
two
centuri
control
human
infecti
diseas
develop
continu
improv
vaccin
technolog
discoveri
dna
immun
fundament
chang
view
natur
vaccin
genet
materi
encod
antigen
rather
actual
antigen
effect
compon
dna
vaccin
new
vaccin
technolog
could
come
import
time
histori
given
increas
threat
emerg
reemerg
infecti
diseas
renew
concern
regard
use
biolog
agent
purpos
bioterror
sinc
incept
dna
vaccin
technolog
undergon
signific
advanc
mani
candid
human
vaccin
formul
alreadi
develop
improv
mode
administr
use
codon
antigen
gene
optim
implement
vaccin
dna
primeboost
regimen
led
quick
progress
dna
vaccin
research
laboratori
bench
human
clinic
trial
biodefens
emerg
infecti
diseas
target
made
signific
contribut
import
process
